Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

New Analysis Shows NME/NAS Submissions in US, EU Hit Five-Year Highs

Posted on: 14 Sep 05

U.S. and EU NME/NAS Submissions Hit Five-Year

Highs in 2004--New Report


The pharmaceutical industry’s new molecular entity (NME) submissions to the U.S. FDA and new active substance (NAS) submissions to the European Medicines Evaluation Agency (EMEA) rose to five-year highs in 2004, according to PAREXEL’s Pharmaceutical R&D Statistical Sourcebook 2005/2006.


The FDA received 31 NME submissions in 2004, while the EMEA received 45 NAS submissions under its centralized registration procedure, through which a drug can gain access to all 25 countries in the European Union via a single approval.


NME/NAS submissions at the FDA and EMEA, which are the regulatory gatekeepers to the world’s two largest pharmaceutical markets, have risen in each of the past two years after bottoming out in 2002.


The NME/NAS submission metric peers further back into the pharmaceutical industry’s new drug development output than the more commonly quoted metric: NME/NAS approvals. And since it is generally accepted that over 80 percent of the NMEs submitted to the FDA are ultimately approved, it provides a preliminary benchmark of likely new drug approvals by the FDA and EMEA in upcoming years.


In the United States, the pharmaceutical industry’s 31 NME submissions in 2004 represent a 23% rise from the many-year low of 24 in 2002. And although the 31 NME submissions equal a five-year high (matching the number in 2000), they remain far off the record levels seen in the mid-1990s.




Annual Number NMEs Filed with U.S. FDA and

NASs Filed with the EU’s EMEA,



                                                FDA                            EMEA


1995                                        48                                --

1996                                        45                                --

1997                                        42                                --

1998                                        43                                --

1999                                        38                                --

2000                                        31                                40

2001                                        30                                40

2002                                        24                                26

2003                                        28                                36

2004                                        31                                45


Source: PAREXEL’s Pharmaceutical R&D Statistical Sourcebook 2005/2006 (


The two-year rise in NAS submissions to the EMEA has been far more dramatic. NAS submissions rose 25% in 2004, and are up 73% over the last two years.



PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2005/2006 is now available at

For more information:

Editor's Details

mark mathieu
PAREXEL International Corp.
978-275-0062, x2176

Last updated on: 27/08/2010

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.